Human cytomegalovirus (HCMV) is a leading cause of severe diseases in immunocompromised 17 individuals, including AIDS and transplanted patients, and in congenitally infected newborns. Despite 18 the availability of several antiviral drugs, their utility is limited by poor bioavailability, toxicity, and 19 resistant strains emergence. Therefore, it is crucial to identify new targets of therapeutic intervention. 20 The dimerization of HCMV DNA polymerase processivity factor UL44 plays an essential role in the 21 viral life cycle being required for oriLyt-dependent DNA replication. We validated the existence of 22 UL44 homodimers both in vitro and in living cells by a variety of approaches, including GST 23 pulldown, thermal shift, FRET and BRET assays. Dimerization occurred with an affinity comparable 24 to that of the UL54/UL44 interaction, and was impaired by amino acid substitutions at the 25 dimerization interface. Subsequently, we performed an in-silico screening to select 18 small 26 molecules (SMs) potentially interfering with UL44 homodimerization. Antiviral assays using 27 recombinant HCMV TB4-UL83-YFP in the presence of the 18 selected SMs led to the identification 28 of four active SMs. The most active one also inhibited AD169 in plaque reduction assays, and 29 impaired replication of an AD169-GFP reporter virus and its ganciclovir-resistant counterpart to a 30 similar extent. As assessed by Western blotting experiments, treatment of infected cells specifically 31 reduced viral gene expression starting from 48 h post infection, consistent with activity on viral DNA 32 synthesis. Therefore, SMs inhibitors of UL44 dimerization could represent a new class of HCMV 33 inhibitors, alternative to those targeting the DNA polymerase catalytic subunit or the viral terminase 34 complex. 35 IMPORTANCE 36 HCMV is a ubiquitous infectious agent causing life-lasting infections in humans. HCMV primary 37 infections and reactivation in non-immunocompetent individuals often result in life-threatening 38 conditions. Antiviral therapy mainly targets the DNA polymerase catalytic subunit UL54 and is often 39 limited by toxicity and selection of drug-resistant viral strains, making the identification of new 40 targets of therapeutic intervention crucial for a successful management of HCMV infections. The 41 49
significance of our work is in identifying the dimerization of the DNA polymerase processivity factor 42 UL44 as an alternative antiviral target. We could show that full length UL44 dimerizes in a cellular 43 context with high affinity and that such interaction could be targeted by small molecules, thus 44 inhibiting the replication of several HCMV strains, including a drug-resistant mutant. Thus, our work 45 could pave the way to the development of a new class of anti-HCMV compounds that act by targeting 46 UL44 dimerization. 47 48 INTRODUCTION specific substitutions on the ability of UL44 to self-interact or to bind the catalytic subunit UL54 were 165 assessed by confocal laser scanning microscopy (CLSM) and fluorescence resonance energy transfer 166 (FRET) acceptor bleaching as described in (47) . For further details please refer to the Appendix 167 section. HEK 293T cells were seeded in a 24-well plate onto glass coverslips (1×10 5 cells/well) and 168 the next day were transfected with 125 and 250 ng of YFP and CFP expression constructs, 169 respectively, using Lipofectamine 2000 (Life Technologies) following the manufacturer's 170 recommendations. At 48 h post-transfection, cells were washed with PBS and fixed with 4% 171 paraformaldehyde for 10' at room temperature. After a wash with milliQ water, the samples were 172 mounted on glass slides with Fluoromount G (Southern Biotech). Samples were imaged by CLSM 173 using a Leica SP2 confocal laser scanning microscope (Leica) equipped with a 63× oil immersion 174 objective. FRET efficiency was determined according to the following formula: FRETeff = [(EDpost 175 − EDpre)/EDpost] × 100, where ED represents the emitted donor fluorescence before (EDpre) or after 176 (EDpost) photobleaching of the acceptor fluorophore. Measurements of at least 20 cells from two 177 independent transfections were used to calculate the box plots. Significance values were calculated 178 by using the unpaired t test with the GraphPad Prism 6 software package (Graphpad Software Inc.). 179 Images were processed using ImageJ (NIH).
180
Bioluminescence resonance energy transfer (BRET) assays. BRET experiments were performed 181 essentially as described previously using a reader compatible with BRET measurements (VICTOR 182 X2 Multilabel Plate Reader, Perkin Elmer) (55). BRET saturation curves were generated using the fused to the C-terminus of the early-late tegument phosphoprotein pp65 (58) was kindly provided by 194 Michael Winkler (Gottingen, Germany). All viral stocks were prepared and titred by immunological 195 detection of IE1/2 proteins as described in (59) or by the plaque reduction method (see below). For 196 details see the appendix section. (1-290) was assessed with software Sitemap (60), using default settings apart from grid 202 resolution which was set as fine. 203 Virtual screening database preparation. A 3D molecular database was built with the Schrodinger 204 suite (Schrödinger) starting from 2D structures taken from the ZINC database 205 (www.zinc.docking.org). A total number of about 3.6 million compounds were selected (Vendors: 206 Asinex, Chembridge, Princeton, NCI and ZINC natural) and downloaded for this study. 2D structures 207 were converted into 3D structures and stereoisomers were generated with the Ligprep function of the 208 Schrodinger suite (Schrödinger). Moreover, for each entry all the possible ionization states at pH 7.0 209 ± 2.0 and tautomers were generated with Epik (Schrödinger). The obtained database consisted of 210 about 5 million compounds. In order to retrieve the most drug-like compounds, ADMET properties 211 of each molecule in the database were predicted with Qikprop (Schrödinger) and compounds were 212 filtered as described in (61) QplogPo/w ≤ 6). Finally, the number of compounds was reduced to about 1.3 million by using the 215 PPI-HitProfiler software with the "soft" mode (CDithem; http://www.cdithem.fr).
216
Virtual screening. For the docking stage, a receptor grid was built on the UL44 structure prepared 217 as above. The grid was centered on the position of residue M116 and receptor grid generation default 218 settings were applied. By using this grid, the database was docked with the High throughput virtual 219 screening (HTVS) scoring function of the Glide software (Schrödinger). After this run, we selected 220 50,000 compounds on the basis of the HTVS docking score. Selected molecules were submitted to a 221 second run of docking using the standard precision (SP) scoring function and only the 5,000 top-222 ranked compounds were selected. Finally, selected molecules were submitted to a run of docking 223 using the extra precision (XP) scoring function and only the 500 top-ranked compounds were 224 selected. After docking, we further narrowed down the number of selected compounds to 18 on the 225 basis of commercial availability, visual inspection, and by a cluster analysis performed with Tanimoto 226 on the basis of the Molprint2D fingerprints of each molecule (62).
227

Preparation of small molecules (SMs) and Ganciclovir (GCV) stocks. Ganciclovir (GCV;
228 Selleckchem, S1878) and small molecules (SMs), with a > 90% purity assessed by liquid 229 chromatography mass spectrometry and high-performance liquid chromatography (Vitas-M 230 Laboratory), were resuspended in 100% DMSO to obtain 20 mM and 50 mM stocks, respectively, 231 and stored at -20°C protected from light. (1.5×10 4 cells/well) were seeded in 96-well special optics black microplates (Corning, CLS3614) and 234 incubated overnight at 37°C, 5% CO 2 and 95% humidity. The next day, cells were infected for 1 h at 235 37 °C in 100 µl/well of DMEM containing TB4-UL83-EYFP at an MOI of 0.03 infectious units/cell.
236
Cells were subsequently washed, and media containing either 0.5% DMSO or two different 237 concentrations (100 and 10 µM) of SMs with a 0.5% DMSO final concentration was added. 50 µM 238 GCV was included as a positive control for inhibition of viral replication. Mock infected cells served 239 as a reference for calculation of background fluorescence. After addition of SMs, the plates were 240 further incubated at 37°C, 5% CO 2 and 95% humidity. Every day, cell confluence and morphology, 241 as well as CPE and the presence of precipitates were evaluated by light microscopy. Fluorescence 242 signals were visualized on an inverted fluorescent microscope (Leica, DFC420 C). Seven days p.i., 243 cells were washed once with PBS and lysed with luciferase lysis buffer (25 mM glycylglycine, 15 244 mM MgSO 4 , 4 mM EGTA, 0.1 % Triton X-100, pH 7.8). Plates were immediately frozen at -20°C, 245 thawed at RT, and fluorescent signals relative to each condition were acquired using a reader 246 compatible with fluorescence measurements (VICTOR X2 Multilabel Plate Reader, Perkin Elmer) 247 equipped with a fluorimetric excitation filter (band pass 485 ± 14 nm) and a fluorimetric emission 248 filter (band pass 535 ± 25 nm). After background subtraction, data were normalized to solvent-treated 249 controls and analyzed with Graphpad Prism (Graphpad Software Inc.). The screening was performed 250 three times, and each plate included at least two wells treated with the same compound, as well as at 251 least 12 wells treated with solvent only.
252
Fluorescent reduction assays (FRA). To calculate the effective dose 50 (ED 50 ) of each compound 253 against TB4-UL83-EYFP virus by means of FRA, MRC5 cells were seeded, infected, treated, and 254 processed as above, using increasing concentrations of each SMs and GCV (range between 0.02 and 255 100 µM). Mock infected cells served as a reference for calculation of background fluorescence. After 256 background subtraction, data were normalized to solvent-treated controls and analyzed with 257 Graphpad Prism (Graphpad Software Inc.). The experiments were performed six times, and each plate 258 comprised at least two wells treated with the same compound, as well as at least 14 wells treated with 259 solvent only. To calculate the ED 50 of each compound against AD169-GFP virus and its GCV-260 resistant AD169-GFP26 counterpart by the means of FRA, MRC5 cells were seeded in 12-well plates 261 (1.8×10 5 cells/well) in 1 ml DMEM supplemented with 10% (v/v) FBS, 50 U/ml penicillin, 50 U/ml 262 streptomycin and 2 mM L-glutamine, and incubated overnight at 37°C, 5% CO 2 and 95% humidity.
263
The next day, cells were infected for 2 h at 37 °C in 1 ml/well of DMEM at MOI of 0.05 infectious 264 units/cell as described in (57). Subsequently, cells were washed with 2 ml of PBS, and 1 ml of medium 265 containing either 0.5% DMSO or increasing concentrations (from 0.001 to 100 µM) of each 266 compound with a 0.5% DMSO final concentration was added. Every day, cell confluence and 267 morphology, as well as CPE and the presence of precipitates were evaluated by light microscopy, 268 whereas fluorescence signals were visualized on an inverted fluorescent microscope (Leica, DFC420 269 C). Seven days p.i., supernatants were collected, cleared from cells and debris by centrifugation for 270 5' at 700 rpm, and stored at -80°C until used for virus yield assays (VIAs) as described below. Cells 271 were washed with 2 ml of ice cold PBS and lysed in 200 µl of GFP lysis buffer (25 mM Tris-HCl, 272 pH 7.8, 2 mM DTT, 2 mM trans-1,2-diaminocyclohexane-N,N,N,N-tetraacetic acid, 1% Triton X-273 100, 10% glycerol [v/v]). Plates were further incubated 10' at 37°C in a humidified incubator, before 274 being incubated for 30' at RT with shaking at 225 rpm. Samples were centrifuged for 5' at 4°C at 275 13,000 rpm and 100 µl of cleared lysates were transferred to black bottomed 96-well plates (Costar, 276 #3916). Fluorescent signals were acquired and analyzed as described above. ). The next day, medium was replaced with serial dilutions of supernatants containing 281 AD169-GFP or AD169-GFP26 virus grown in the presence of inhibitory compounds. One week later, 282 virus yield relative to each condition was calculated and expressed as 50% Tissue Culture Infectious 283 Dose (TCID 50 )/ml using the Spearman and Karber algorithm as described in (63).
284
Plaque reduction assays. For plaque reduction assays (PRA) human foreskin fibroblast (HFF) cells 285 were seeded in 24-well plates (2×10 5 cells/well). The following day cells were infected at 37°C with 286 70 Plaque Forming Unit (PFU) of HCMV AD169 per well in DMEM containing FBS 5%. At 2 h p.i., 287 the inocula were removed, cells were washed, and media containing various concentrations of each 288 compound, 5% FBS, and 0.6% methylcellulose were added. All compound concentrations were tested 289 at least in triplicate. After incubation at 37°C for 10-11 days, cell monolayers were fixed, stained with 290 crystal violet, and viral plaques were counted. were analyzed by SDS page/Western blotting as described previously (49). The following antibodies, 310 diluted in PBS containing 0.2% Tween20 and 5% milk (w/v), were used: a-His 6 mAb (Sigma Aldrich, 311 #H-1029; 1:2,500), a-IE1&2 mAb (Virusys Corporation, #CA003-1; 1:10,000), a-UL44 mAb 312 (Virusys Corporation, #P1202-1; 1:100); a-pp65 mAb (Virusys Corporation, #P1251; 1:2,000); a-313 pp28 (Abcam, #ab6502; 1:10,000), rabbit a-GADPH pAb (Santa Cruz Biotech, #sc-25778; 1:5,000); 314 mouse a-b-Actin mAb (Sigma Aldrich, # A5316 1:5,000); goat a-mouse (Santa Cruz Biotech, #sc-315 2055; 1:10,000) and a-rabbit (Sigma Aldrich, #A6154; 1:10,000) immunoglobulin Abs conjugated 316 to horseradish peroxidase. Signals were acquired using an imaging system (Alliance Mini, Uvitech) 317 and quantified using Image J (NIH). 
RESULTS
320
Full length UL44 dimerizes in vitro and a few residues are essential for self-interaction. All data 321 relative to UL44 dimerization in vitro rely on the deletion mutant UL44(1-290), which lacks the 322 highly unstructured C-terminal domain of the protein. Therefore, we investigated whether full length 323 UL44 similarly dimerizes in vitro by means of GST-pulldown assays ( Figure 1A ). Our results indicate 324 that His 6 -UL44 could be specifically pulled down by GST-UL44 but not by GST alone ( Figure 1A (41), we decided to further corroborate our findings by comparing the stability of His 6 -UL44 330 and its L86A/L87A derivative by thermal shift assays (TSAs). To this end, we initially performed a 331 small-scale screening to identify the most suitable conditions to assess UL44 stability by TSA 332 (Supplementary Figure S1 ). Our data indicated that His 6 -UL44 is significantly less stable as compared Figure S1GH ). Such analysis allowed us to 336 identify the 3 most suitable buffer conditions to assess UL44 stability by TSA (Supplementary Figure 337 S1IJ). We next compared the effect of the L86A/L87A double substitution on UL44 stability. Our 338 results showed that His 6 -UL44 is significantly more stable than His 6 -UL44-L86A/L87A 339 (Tm=52+0.3°C vs. 42.4+1.4°C, respectively, in the three buffers tested, see Figure 2B ), consistent 340 with the involvement of L86 and L87 in protein dimerization.
341
UL44 dimerizes in cells and a few residues are essential for self-interaction. We have previously 342 shown that different UL44 variants can reciprocally influence their subcellular localization by CLSM 343 analysis of GFP and DsRed2 fusions (23, 26), suggesting that the protein can also exist as a dimer in 344 a cellular context. However, interpretation of such relocalization assays could be complicated by 345 experimental artefacts due to DsRed2 oligomerization (64). We therefore decided to further 346 corroborate such findings by fluorescent energy transfer (FRET) assays. To this end, HEK 293T cells 347 were transfected with plasmids mediating the expression of CFP-UL44 or its L86A/L87A and I135A 348 derivatives, expected to be impaired in dimerization and in binding to UL54, respectively. Cells were 349 also co-transfected with plasmids expressing YFP-tagged UL44 and the C-terminus of UL54 bearing 350 the UL44-binding domain (amino acids 1125-1242). Cells were also transfected to express CFP and 351 YFP individually, as negative controls, or a CFP-YFP fusion protein, as a positive control. We bearing the I35A substitution, which prevents the interaction with UL54 in vitro (7.7+0.5; n=97).
372
Clearly, these data indicate that full length UL44 exists as a dimer in a cellular context, and 373 dimerization relies on residues identified in the crystal structure of its N-terminal domain.
374
UL44 self-interacts in cells with an affinity comparable to that of the UL44-UL54 interaction. 375 Previous studies proposed the UL44-UL54 interaction as a potential target for therapeutic 376 intervention and identified SMs inhibiting HCMV replication by interfering with holoenzyme 377 formation (48, 65). Our data suggest that UL44 dimerization surface might be a similarly suitable 378 target for the development of antivirals. In vitro, the affinity of UL44 self-interaction has been 379 reported to be similar to that of the UL44-UL54 interaction, although using different methods and 380 thus not being directly comparable (16, 22) . We therefore decided to compare the affinity of such Figure S2CD) . These data suggest that BRET can be used to quantify UL44 self-396 interaction in living cells. Importantly, when BRET saturation experiments were performed by 397 transfecting cells with a fixed amount of BRET donor plasmid RLuc-UL44 or RLuc-UL44(405-433) 398 in the presence of increasing amounts of BRET acceptor plasmid YFP-UL44, the BRET ratio relative 399 to RLuc-UL44 and YFP-UL44 promptly reached saturation, whereas the BRET ratio relative to 400 RLuc-UL44(405-433) and YFP-UL44 did not ( Figure 3A ). Data fitting allowed us to calculate the 401 Bmax value, corresponding to the maximal BRET ratio obtainable for a BRET pair, and the B 50 value, 402 corresponding to the ratio between BRET acceptor and donor sufficient to generate a BRET ratio 403 corresponding to half of the Bmax, and indicative of the affinity of UL44 self-interaction in living 404 cells. Similar BRET saturation experiments were performed for RLuc-UL54/YFP-UL44 in order to 405 compare UL44 dimerization and UL44 binding to UL54 ( Figure 3B ). Importantly, UL44 appeared to 406 self-interact with an affinity similar to that of the UL54-UL44 interaction, as suggested by the very Table I ). The same approach was 409 then used to study the effect of specific UL44 substitutions on its homodimerization and on UL54 410 binding (see Table I ). Importantly, substitutions at the UL44 dimerization interface (F121A, 411 L86A/L87A) specifically increased the B 50 value relative to UL44 dimerization but not that relative 412 to binding to UL54, implying that the corresponding proteins were not misfolded (see Figure 3D , E 413 and Table I ). On the other hand, the I135A substitution specifically increased the B 50 value relative 414 to binding to UL54 but not that relative to UL44 dimerization. As expected, the Dloop and DNLS 415 substitutions did not affect either process. Thus, UL44 self-interacts in living cells with an affinity 416 comparable to that of the UL44-UL54 interaction and single amino acid substitutions at the 417 dimerization interface strongly impair the process.
418
An in-silico screening identifies small molecules potentially interfering with UL44 dimerization. 419 We aimed at identifying small molecules (SMs) interfering with UL44 self-interaction. To this end, 420 the published crystal structure of UL44 ( Figure 4A ) was analyzed with SiteMap to identify top-ranked 421 potential receptor binding sites on the protein monomer. Our analysis identified 3 sites as potential 422 receptor binding sites, one of which sites is located at the interface between the two monomers (Figure 423 4B). Such pocket has a druggability score (Dscore) of @ 0.8 according to SiteMap (0.797) and it is 424 therefore potentially druggable (60). The key residues seem to be L87 and especially L86, which are 425 located in a cavity formed by the residues F121, M123, M116, L93, C117, K101, T100, A118, L99, 426 S96, D98 and P119 of the other monomer. Therefore, the center of the grid built for the docking 427 calculation was set on M116 and such structure was used to screen about 1.3 million compounds from 428 the ZINC database using the Glide software ( Figure 4C ). Eighteen of these molecules were purchased 429 and used for further assays (Supplementary Figure S3 and Supplementary Tables I and II) . dose-dependent manner, with ED 50 values in the low micromolar range ( Figure 6 ). As expected, GCV 451 efficiently inhibited HCMV replication with a ED 50 of 2.3+0.7 µM and did not cause detectable 452 cytotoxic effects at any concentration tested ( Figure 6 ). Among the SMs tested B6 was the most active 453 compound and exhibited an ED 50 slightly lower that that calculated for GCV (2.5+0.7 µM). However, Overall, our data indicate that SM B3 might be specifically interfering with HCMV life cycle.
461
Analysis of its predicted binding mode to UL44 revealed several hydrophobic interactions with UL44 462 residues M116, C117, A118, P119, F121, M123, L99, L93 as well as two H-bond interactions with 463 S96 (Figure 7) . The ability to B3 to inhibit HCMV AD169 replication in HFF was also assessed by 464 PRA assays (not shown), resulting in a ED 50 of 16.3+8.5 µM (n=4). Table II ) revealed that GCV inhibited more efficiently replication of the AD169-GFP virus 474 than of AD169-GFP26 (ED 50 of 2.6+0.8 µM and 20.0+4.3 µM, respectively; n=5), while AD169-475 GFP and AD169-GFP26 appeared equally sensitive to B3 (ED 50 of 9.0+0.3 µM and 21.1+4.7 µM, 476 respectively; n=5). Very similar results were obtained after quantification of viral progeny in VYAs 477 ( Figure 8C, D) . Indeed, GCV inhibited more efficiently viral production of HCMV AD169 (ED 50 of 478 0.5+0.47 µM; n=3) as compared to AD169-GFP26 (ED 50 of 4.5+4.5 µM; n=3), whereas B3 did not 479 (ED 50 of 5.3+1.8 µM and 6.1+5.9 µM, respectively). Thus, B3 appears to efficiently impair 480 replication of both GCV-sensitive and GCV-resistant HCMV.
481
B3 selectively impairs HCMV late gene expression. In order to characterize the mode of action of 482 B3, MRC5 cells were infected with AD169 at an MOI of 1 infectious units/cell for 2 h and expression 483 of immediate-early (IE1/2), early-late (UL44 and pp65), and late (pp28) proteins was assessed at 484 different time points p.i. As expected, neither GCV nor B3 treatment affected IE1/2 expression at 6 485 and 12 h p.i., indicating that the observed decrease in viral replication did not depend on an inhibition 486 of activity on the major IE promoter ( Figure 9A, B) . Similarly, UL44 and pp65 levels were not This is the first study directly targeting the dimerization of HCMV DNA polymerase accessory 496 subunit UL44. The latter is an interesting therapeutic target considering the interaction interface 497 shown in the crystal structure of UL44(1-290), and the fact that single amino acid substitutions 498 affecting dimerization in vitro also impaired dsDNA binding (16) and prevented oriLyt dependent 499 DNA replication in trans-complementation assays (23). Our new data presented here further 500 strengthened this hypothesis, by showing that the same substitutions affect dimerization of full length 501 UL44 both in vitro and in living cells (see Figs. 1-4) . Indeed, the L86A/L87A substitution reduced 502 binding to GST-UL44 in pulldown assays ( Figure 1A) , and greatly reduced protein stability in TSA 503 ( Figure 1B) . The latter observation is consistent with the fact that shown that substitutions affecting 504 protein multimerization decrease the Tm (41). Similarly, the L86A/L87A substitution reduced FRET 505 efficiency and the B 50 value for UL44 self-interaction, but had little or no effect on the ability of the 506 protein to bind to its catalytic subunit UL54 (Figures 2 and 3) , therefore suggesting that the protein 507 was still properly folded. Intriguingly, substitutions preventing nuclear translocation or DNA binding 508 of UL44 did not prevent its dimerization or binding to the DNA polymerase catalytic subunit UL54, 509 as exemplified by B 50 values very similar to the wild-type protein, and consistently with our 510 previously published model whereby UL44 dimerizes and associates with UL54 in the cytosol before 511 nuclear import (3, 26). However, both substitutions significantly reduced the Bmax values as 512 compared to the wild-type protein, which is possibly due to a change in protein conformation (and 513 therefore energy transfer between BRET donor and acceptor subunits) of UL44 homodimers upon 514 DNA binding. It is worth mentioning that, while the L86A/L87A substitutions similarly caused a 515 decrease in the Bmax value relative to UL44 dimerization, the F121A substitution did not. This is 516 interesting and consistent with the evidence that the F121A variant binds to DNA with a 10-fold 517 greater affinity than the L86A/L87A variant and the hypothesis that it still presents weak DNA 518 binding upon dimerization (16). Regardless of the effects of DNA binding on the HCMV holoenzyme 519 conformation, which are currently being investigated in our laboratory, our data show that UL44 520 interactions with UL54 and with itself occur with similar affinity, as implied by the very similar B 50 521 values ( Figure 3 and Table I ; (56)). Therefore, given the fact that previous studies have identified 522 peptides and SMs able to successfully block HCMV replication by interfering with the interaction 523 between UL54 and UL44 (50, 51, 65), these results prompted us to perform a virtual screening aimed 524 at identifying SMs inhibiting UL44 dimerization (Figure 4) . One of the 18 SMs tested was capable 525 of inhibiting HCMV replication in a variety of assays, although with different efficacy. ED 50 values 526 ranged from 4.2 (FRA) to 16.3 µM (PRA), while those determined for GCV were comprised between 527 0.5 (VYA) and 2.6 (FRA) µM (Table III) . The ED 50 values calculated here for GCV are compatible 528 with those reported previously in the literature, with some variance being attributable to intrinsic 529 differences between the different assays and viruses tested. For example, FRA with the TB40-UL83-530 EYFP virus rely on the measurement of pp65 expression, which is expressed with an early-late 531 kinetic, whereas the expression of the reporter gene in the AD169-GFP virus is under control of the 532 IE promoter (57, 58) . Importantly, B3 inhibited the AD169-GFP virus and its GCV-resistant 533 derivative AD169-GFP26 with almost identical ED 50 values in both FRA and virus yield reduction 534 assays while GCV, as expected, was much more active towards AD169-GFP (see Figure 8 and Table   535 II). Although we did not formally prove here that B3 acts by disrupting the UL44 homodimer during 536 viral infection, the fact that it inhibits HCMV gene expression starting from 48 p.i., and strongly 537 inhibits late gene expression at 72 and 96 h p.i., in a very similar fashion to GCV (Figure 9 ) is 538 compatible with inhibition of viral DNA replication (66-68). Therefore, our results raise hopes in 539 terms of potential use of HCMV dimerization inhibitors for the treatment of patients infected with 
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Proteins Expression and Purification. Cells were grown in LB medium containing 100 µg/ml 759 ampicillin until the OD 600 was 0.8 and then induced by the addition of 0.3 mM IPTG for 3 h at room 760 temperature (RT). Cells were pelleted, resuspended in lysis buffer (50 mM NaH 2 PO 4 , 500 mM NaCl, 761 10% glycerol, 10 mM imidazole, 1 mg/ml lysozyme, and Complete protease inhibitors), and then 762 lysed by two freeze/thaw cycles followed by sonication. The lysate was centrifuged at 13,000 rpm 763 for 45 min, applied to a 0.5-ml Ni-NTA agarose resin column (Qiagen) that had been equilibrated in 764 lysis buffer, and then washed with wash buffer 1 (50 mM NaH 2 PO 4 , 500 mM NaCl, 10% glycerol, 765 and 20 mM imidazole) and subsequently with wash buffer 2 (50 mM NaH 2 PO 4 , 500 mM NaCl, 10% 766 glycerol, and 50 mM imidazole). Finally, proteins were eluted with elution buffer (50 mM NaH 2 PO 4 , 767 500 mM NaCl, 10% glycerol, and 250 mM imidazole). Purified proteins were dialyzed against 20 768 mM Tris-HCl pH 7.5, 150 mM NaCl, 30% glycerol, 0.1 mM EDTA, 2 mM DTT and stored at -80°C. were added to each well of the 96 well plate, and cells were further incubated at 37°C with 5% CO 2 783 for 2 h. Subsequently, cells were lysed by gently pipetting in 100 µl of Lysis Buffer (SDS 10%, 0.01M
784
HCl in H 2 0). Plates were then incubated overnight at 37°C. Absorbance was determined with a 785 spectrophotometer plate reader at 620 nm (Sunrise, Tecan). Data were exported to excel and Similarly, the BRET ratio, defined as the difference between the BRET value relative to a BRET pair 812 and the BRET value relative to the BRET donor alone, was calculated according to the formula: were infected with TB4-UL83-EYFP and treated with increasing concentrations of the indicated 882 compounds. In parallel, uninfected MRC5 cells were also treated for assessment of SMs cytotoxicity.
883
Seven days post treatment, cells were processed for data acquisition and analysis as described in the were infected with either AD169-GFP virus or its GCV-resistant counterpart AD169-GFP26 treated 902 with increasing concentrations of the indicated compounds. At 7 days p.i., cells were lysed and plates 903 processed for fluorimetric analysis using a plate reader and supernatants collected for virus yield 904 reduction assays (A, C) . MRC5 cells were infected with serial dilutions of supernatants derived from 905 infected cells. At 7 days p.i., viral titers were calculated using the TCID 50 method (B, D). Data from 906 both assays were used to calculate the ED 50 s relative to the two viruses (A, B) as well as the ratio 907 between the ED 50 calculated for AD169-GFP26 and AD169-GFP (C, D) relative to GCV and B3.
908
Data shown are single measurements, means, and standard deviations of at least three independent 909 experiments, along with the p-value relative to the Student's t-test the indicated groups; *: p ≤ 0.05. BRET saturation curves such as those shown in Figure 3 A 
